ATE534669T1 - Verfahren zum erhalten von anti-idiotyp antikörpern - Google Patents
Verfahren zum erhalten von anti-idiotyp antikörpernInfo
- Publication number
- ATE534669T1 ATE534669T1 AT03725556T AT03725556T ATE534669T1 AT E534669 T1 ATE534669 T1 AT E534669T1 AT 03725556 T AT03725556 T AT 03725556T AT 03725556 T AT03725556 T AT 03725556T AT E534669 T1 ATE534669 T1 AT E534669T1
- Authority
- AT
- Austria
- Prior art keywords
- idiotype antibodies
- obtaining anti
- peptides
- idiotype
- obtaining
- Prior art date
Links
- 230000003302 anti-idiotype Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000003278 mimic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38313602P | 2002-05-28 | 2002-05-28 | |
PCT/IL2003/000424 WO2003099868A2 (en) | 2002-05-28 | 2003-05-22 | Method for obtaining anti-idiotype antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE534669T1 true ATE534669T1 (de) | 2011-12-15 |
Family
ID=29584513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03725556T ATE534669T1 (de) | 2002-05-28 | 2003-05-22 | Verfahren zum erhalten von anti-idiotyp antikörpern |
Country Status (7)
Country | Link |
---|---|
US (2) | US8450067B2 (de) |
EP (1) | EP1511772B1 (de) |
JP (4) | JP4489582B2 (de) |
AT (1) | ATE534669T1 (de) |
AU (1) | AU2003228084A1 (de) |
IL (2) | IL165364A0 (de) |
WO (1) | WO2003099868A2 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003228084A1 (en) * | 2002-05-28 | 2003-12-12 | Omrix Biopharmaceuticals Inc. | Method for obtaining anti-idiotype antibodies |
JP4991544B2 (ja) * | 2004-08-23 | 2012-08-01 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | ストレス応答を媒介するためのペプチド阻害剤 |
EP2258727A1 (de) | 2009-05-27 | 2010-12-08 | Wezen Biopharmaceuticals S.r.l. A Socio Unico | Immunglobulinzubereitung zur Behandlung einer Autoimmunerkrankung und Immunsystemstörungen |
JP5985481B2 (ja) * | 2010-09-01 | 2016-09-06 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 抗イディオタイプ抗体の迅速な産生 |
CN103502515B (zh) * | 2011-01-10 | 2015-12-23 | Opko制药公司 | 自身免疫疾病的抗原替代物 |
US20140088017A1 (en) | 2011-05-23 | 2014-03-27 | Yeda Research And Development Co., Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
WO2013098419A1 (en) * | 2011-12-28 | 2013-07-04 | Immunoqure Ag | Method of providing monoclonal auto-antibodies with desired specificity |
US10131709B2 (en) | 2011-12-28 | 2018-11-20 | Immunoqure Ag | Nucleic acid molecules encoding monoclonal antibodies specific for IL-22 |
CN104603274B (zh) * | 2012-08-05 | 2020-08-18 | Absci有限责任公司 | 可诱导共表达系统 |
CN105518025B (zh) | 2013-07-03 | 2020-12-08 | 因美诺克股份公司 | 人抗IFN-α抗体 |
EP4015539A1 (de) * | 2020-12-16 | 2022-06-22 | Cryolab S.r.l. | Verfahren zur herstellung von menschlichen monoklonalen antiidiotypischen antikörpern |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4690905A (en) | 1983-11-16 | 1987-09-01 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method for removal of human antibodies to native DNA from serum |
US5068177A (en) * | 1983-12-28 | 1991-11-26 | Scripps Clinic And Research Foundation | Anti-idiotype antibodies induced by synthetic polypeptides |
CA1256795A (en) * | 1983-12-28 | 1989-07-04 | Dennis A. Carson | Anti-idiotype antibodies induced by synthetic polypeptides |
US6270771B1 (en) * | 1988-10-06 | 2001-08-07 | Institut Pasteur | Peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes |
FR2672290B1 (fr) * | 1991-02-05 | 1995-04-21 | Pasteur Institut | Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t. |
US5882879A (en) * | 1990-02-28 | 1999-03-16 | Gist-Brocades, N.V. | Method for influencing β-lactam antibiotic production and for isolation of large quantities of ACV synthetase |
US6864060B1 (en) * | 1993-03-31 | 2005-03-08 | Cadus Technologies, Inc. | Yeast cells expressing modified G proteins and methods of use therefor |
IL113159A0 (en) | 1995-03-28 | 1995-06-29 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
EP1007628B1 (de) * | 1996-09-26 | 2006-03-15 | The Regents of the University of Colorado | Transgenes modell für herzversagen |
WO1998026086A1 (en) * | 1996-12-11 | 1998-06-18 | University Of Florida | Novel methods and compositions for treatment of autoimmune diseases |
US6183997B1 (en) * | 1997-03-21 | 2001-02-06 | Stratagene | Polymerase enhancing factor (PEF) extracts PEF protein complexes isolated PEF proteins and methods for purifying and identifying same |
US7041490B1 (en) * | 1997-11-28 | 2006-05-09 | Serono Genetics Institute, S.A. | Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same |
US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
US7504490B1 (en) * | 1998-10-16 | 2009-03-17 | Oscient Pharmaceuticals Corporation | Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics |
WO2001064835A2 (en) * | 2000-02-28 | 2001-09-07 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
US20080229439A1 (en) * | 1999-05-06 | 2008-09-18 | La Rosa Thomas J | Nucleic acid molecules and other molecules associated with transcription in plants and uses thereof for plant improvement |
US20100293669A2 (en) * | 1999-05-06 | 2010-11-18 | Jingdong Liu | Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
AU5011400A (en) * | 1999-05-14 | 2000-12-05 | Arbor Vita Corporation | Molecular interactions in t cells |
US20050037969A1 (en) * | 1999-05-14 | 2005-02-17 | Arbor Vita Corporation | Molecular interactions in hematopoietic cells |
EP1224223A4 (de) * | 1999-09-24 | 2004-08-11 | Univ Monash | Immuninteraktive moleküle und deren verwendungen bei der behandlung von patientenmit hev b 5 allergien |
EP1268552A2 (de) * | 1999-12-30 | 2003-01-02 | Frank, Hans-Georg c/o Lehrstuhl für Anatomie II Universitätsklinikum der RWTH | Verfahren zur identifizierung von substanzen, die säugetier-epitope nachahmen |
WO2001081581A2 (en) * | 2000-04-21 | 2001-11-01 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of acne vulgaris |
AU2001271839A1 (en) * | 2000-07-05 | 2002-01-14 | Pharmacia And Upjohn Company | Human ion channels |
US6569431B2 (en) * | 2000-10-17 | 2003-05-27 | The Regents Of The University Of California | Recombinant antibody fragments as autoantibody antagonists |
EP1399187A4 (de) * | 2000-10-18 | 2005-09-21 | Sloan Kettering Inst Cancer | Anwendungen des monoklonalen antikörpers 8h9 |
MXPA03003690A (es) * | 2000-10-27 | 2004-05-05 | Chiron Spa | Acidos nucleicos y proteinas de los grupos a y b de estreptococos. |
US7214786B2 (en) * | 2000-12-14 | 2007-05-08 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
WO2002079449A2 (en) * | 2001-03-28 | 2002-10-10 | Incyte Genomics, Inc. | Molecules for disease detection and treatment |
US7335467B2 (en) * | 2001-05-15 | 2008-02-26 | Ludwig Institute For Cancer Research | Breast cancer antigens |
US20030235833A1 (en) * | 2001-06-18 | 2003-12-25 | National Institute Of Advanced Industrial Science And Technology | Guanosine triphosphate-binding protein coupled receptors |
AU2003228084A1 (en) * | 2002-05-28 | 2003-12-12 | Omrix Biopharmaceuticals Inc. | Method for obtaining anti-idiotype antibodies |
-
2003
- 2003-05-22 AU AU2003228084A patent/AU2003228084A1/en not_active Abandoned
- 2003-05-22 IL IL16536403A patent/IL165364A0/xx unknown
- 2003-05-22 JP JP2004508122A patent/JP4489582B2/ja not_active Expired - Fee Related
- 2003-05-22 EP EP03725556A patent/EP1511772B1/de not_active Expired - Lifetime
- 2003-05-22 WO PCT/IL2003/000424 patent/WO2003099868A2/en active Application Filing
- 2003-05-22 US US10/515,499 patent/US8450067B2/en active Active
- 2003-05-22 AT AT03725556T patent/ATE534669T1/de active
-
2004
- 2004-11-24 IL IL165364A patent/IL165364A/en active IP Right Grant
-
2009
- 2009-12-28 JP JP2009297605A patent/JP5727133B2/ja not_active Expired - Fee Related
- 2009-12-28 JP JP2009297606A patent/JP5149269B2/ja not_active Expired - Fee Related
-
2013
- 2013-02-22 JP JP2013033225A patent/JP2013100361A/ja active Pending
- 2013-05-26 US US13/902,836 patent/US10040869B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP5727133B2 (ja) | 2015-06-03 |
WO2003099868A3 (en) | 2004-01-15 |
AU2003228084A1 (en) | 2003-12-12 |
WO2003099868A2 (en) | 2003-12-04 |
US20130244925A1 (en) | 2013-09-19 |
JP2010150260A (ja) | 2010-07-08 |
IL165364A0 (en) | 2006-01-15 |
US10040869B2 (en) | 2018-08-07 |
JP2013100361A (ja) | 2013-05-23 |
JP2006505503A (ja) | 2006-02-16 |
JP4489582B2 (ja) | 2010-06-23 |
EP1511772A2 (de) | 2005-03-09 |
WO2003099868B1 (en) | 2004-04-01 |
JP2010163431A (ja) | 2010-07-29 |
US20060078943A1 (en) | 2006-04-13 |
US8450067B2 (en) | 2013-05-28 |
EP1511772B1 (de) | 2011-11-23 |
JP5149269B2 (ja) | 2013-02-20 |
IL165364A (en) | 2013-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005018424A3 (en) | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits | |
ATE534669T1 (de) | Verfahren zum erhalten von anti-idiotyp antikörpern | |
IL171356A (en) | Anti-interferon receptor antibody for treatment of inflammatory bowel disease | |
HUP9802212A2 (hu) | Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok | |
DE602006011934D1 (de) | Verfahren zum nachweis von bei rheumatoider arthritis gebildeten autoantikörpern | |
EA200501017A1 (ru) | Астма и модуляторы аллергических воспалений | |
HUP0401591A2 (hu) | Új receptor-nukleinsavak és- polipeptidek | |
DE69431060T2 (de) | Klonierte glutaminsäure-decarboxylase | |
FI960727A (fi) | Neurokiniiniantagonisteina käyttökelpoiset heterosyklit | |
ATE454901T1 (de) | Verfahren zur erhaltung zellimmuneantworten gegen proteinen | |
CY1112330T1 (el) | Πρωτεϊνες συνδεσης gag | |
ATE404587T1 (de) | Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen | |
MA27880A1 (fr) | Derives de tetrahydrocarbazole et leur utilisation pharmaceutique | |
DE60217698D1 (de) | Behandlung chronischer gelenkentzündung unter verwendung eines antikörpers gegen das cd3 antigenkomplex | |
BRPI0415281A (pt) | antagonistas de receptor de acetilcolina muscarìnico | |
WO2006002195A3 (en) | Method of complexing a protein by the use of a dispersed system and proteins thereof | |
DE60332481D1 (de) | Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems | |
DE60327925D1 (de) | Verwendung von löslichem fgl2 als immunosuppressivum | |
DE60330780D1 (de) | Sequenzen des t-zellrezeptors cdr3 und nachweisverfahren | |
WO2005058358A3 (en) | Use of agents derived from ceacam1 for the treatment of inflammatory diseases | |
IS7558A (is) | Blanda af NMDA mótlyfi og asetýlkólín esterasa hindrum fyrir meðhöndlun á Alzheimers-sjúkdómnum | |
HUP0301111A2 (hu) | Potenciálisan immundomináns acetilkolin-receptor oligopeptideket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
FR2834717B1 (fr) | Mutants de la proteine tat du virus vih-1 | |
ES2193601T3 (es) | Utilizacion de peptidos de citrulina derivados a la filagrina en el marco del tratamiento de enfermedades autoinmunes. | |
CY1115126T1 (el) | Μεθοδος και εμβολιο που περιλαμβανει συμπολυμερες 1 για θεραπεια ψυχιατρικων διαταραχων |